Amgen Inc.
AMGNHealthcare Drug Manufacturers General
Amgen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.8 billion, up 9.95% from fiscal 2024.
- Revenue
- +8.45%
- EPS
- +19.4%
- Free cash flow
- −14.0%
- Total debt
- −1.06%
Quarter to September 2026, against a year earlier
Follow AMGN
Alert me
Amgen Inc. (AMGN) Shares outstanding
Amgen Inc.'s shares outstanding at the end of fiscal 2025 was $542.0M, unchanged from fiscal 2024. At the end of the quarter to Sep 30, 2026 it was $546.0M. Over the past ten years it has ranged from $538.0M (fiscal 2023) to $766.0M (fiscal 2015); the current reading is higher than 36% of that period. Amgen Inc. ranks 14th of 20 Drug Manufacturers General companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $542.0M | 0.18% |
| FY2024 | $541.0M | 0.56% |
| FY2023 | $538.0M | (0.55%) |
| FY2022 | $541.0M | (5.58%) |
| FY2021 | $573.0M | (2.88%) |
| FY2020 | $590.0M | (3.12%) |
| FY2019 | $609.0M | (8.42%) |
| FY2018 | $665.0M | (9.52%) |
| FY2017 | $735.0M | (2.52%) |
| FY2016 | $754.0M | (1.57%) |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $546.0M | 0.37% |
| Jun 2026 | $544.0M | 0.00% |
| Mar 2026 | $544.0M | 0.37% |
| Dec 2025 | $542.0M | 0.00% |
| 43 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| PFE Pfizer Inc. compare | $5.8B |
| NVO Novo Nordisk A/S compare | $4.4B |
| MRK Merck & Co., Inc. compare | $2.5B |
| BMY Bristol Myers Squibb Company compare | $2.1B |
| NVS Novartis AG compare | $1.9B |
| ABBV AbbVie Inc. compare | $1.8B |
| AZN AstraZeneca PLC compare | $1.6B |
| GILD Gilead Sciences, Inc. compare | $1.3B |
| AMGN Amgen Inc. | $546.0M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on AMGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement